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Abstract 
Serum albumin is the main drug transporter of the bloodstream and contains two main binding sites:  
Sudlow I or acidic drug binding site, and Sudlow II or benzodiazepine binding site. Warfarin, a well-known 
anticoagulant drug commonly used in the prevention of thrombosis and thromboembolism, binds to 
Sudlow I site, whereas non-steroidal antiinflammatory drugs (NSAIDs) such as diflunisal bind preferentially 
to Sudlow II site.  Albumin is a fluorophore that modifies its fluorescence (quenching or enhancement 
effect) when it is bound to a drug. The application of the double logarithm Stern-Volmer equation allows 
the calculation of the stoichiometry and the binding constant of the process. This procedure does not 
consider the possible interferences coming from the fluorescence of the drug though. Another strategy to 
evaluate the binding constants is to consider the whole spectrum, taking into account all the possible 
species in equilibrium; in this case we have used an extended version of the STAR program, which can deal 
with 300 spectra, each containing up to 300 data points. The aim of this work is to compare both 
approaches to evaluate the interaction between warfarin (Sudlow I) and diflunisal (Sudlow II) and HSA: the 
double logarithm Stern-Volmer equation and the STAR program. 
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Introduction 
Albumin, the most abundant protein in plasma and serum, is a water-soluble macromolecule with high 
biological significance. It is able to maintain the plasma oncotic pressure and modulate the fluid 
distribution among body compartments. Native albumin, that is the one without ligands or bound 
molecules, is built up from three homologous domains (I, II and III), showing each one two distinct 
subdomains, named A and B. There are numerous binding sites on albumin, but drugs and other exogenous 
compounds bind, mainly, to two of them: Sudlow I or acidic drug binding site, placed on subdomain IIA, 
and Sudlow II or benzodiazepine binding site, located on subdomain IIIA. Thus, albumin plays a relevant 
role in binding and transport functions and, therefore, in the pharmacokinetics of drugs [1].  
Drug-albumin interactions can be evaluated using several complementary techniques such as 
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isothermal titration calorimetry, fluorescence, frontal analysis capillary electrophoresis or equilibrium 
dialysis [2,3]. In the case of fluorescence, the albumin is considered as the main fluorophore, as it contains 
three fluorescent amino acids (tryptophan, tyrosine and phenylalanine). When the complex drug-protein is 
formed, the albumin fluorescence can be either quenched or enhanced. There are some equations to 
evaluate the fluorescence quenching/enhancement that allow calculating the binding parameters (binding 
constant and stoichiometry) [4]. These equations present several drawbacks, as they consider the albumin 
as the unique fluorophore, and assume that only one type of interaction is formed and that the 
concentration of the free drug is much higher than the bound fraction. However, there often exist other 
fluorophores in solution (such as the drug or a drug-albumin complex) that force to work under more 
selective but less sensitive conditions. Another strategy to evaluate the binding constants is to consider the 
whole fluorescence spectrum, taking into account all the possible species in equilibrium.  
 The aim of this work is to evaluate the interaction between warfarin, interacting into Sudlow I, or 
diflunisal, interacting into Sudlow II with human serum albumin (HSA) by fluorescence, using both 
approaches to calculate the binding parameters and compare the results obtained. 
Experimental  
HSA (99 %), warfarin (>99 %), and diflunisal (>98 %) were obtained from Sigma-Aldrich (St Louis, MO, 
United States). Hydrochloric acid (0.5 M), sodium dihydrogen phosphate monohydrate (>99 %), disodium 
hydrogen phosphate (>99 %), sodium chloride (>99 %), and potassium chloride (>99 %) were from Merck 
(Darmstadt, Germany). Water was purified by a Milli-Q plus system from Millipore (Bedford, MA, United 
States), with a resistivity of 18.2 MΩ cm. PBS (phosphate buffer solution) (10 mM, I=150 mM) consisted of 
an aqueous solution containing 0.137 M NaCl, 0.0027 M KCl, 0.0015 mM KH2PO4·3H2O and 0.0081 M 
Na2HPO4·H2O. The solution pH was adjusted to 7.40 with 0.5 M HCl. Drugs and albumin were dissolved in 
PBS at the desired concentration (300 - 1000 µM and 3 µM, respectively).  
Quenching studies were carried out by titration over a HSA solution (2.7 mL) with an initial 
concentration of 3 µM. The albumin was placed in a fluorescence cuvette at 25 °C. The initial fluorescence 
spectrum was recorded. Sixteen successive additions of the drug under study (warfarin, or diflunisal) were 
done to cover a drug concentration in the range 0.4 – 14 µM. After each addition, the solution in the 
cuvette was stirred to allow the temperature and reaction equilibration. Then, the fluorescence spectrum 
was acquired using a Cary Eclipse fluorimeter from Agilent Technologies (Santa Clara, MA, United States) 
[4] using 5 nm slits in both, excitation and emission monochromators. These protein and drug 
concentrations allow measuring the specific binding of the drug to the protein and do not correspond to 
the plasmatic ones. In fact, the usual albumin concentration in plasma is about 600 µM and the 
drug:albumin ratio is usually as low as 1:150 for warfarin (30 mg/week) [5] and 1:2 for diflunisal (500 mg, 
single dose) [6]. 
Data treatment 
Fluorescence data were recorded in three ways: a standard fluorescence spectrum, and as synchronous 
fluorescence spectra at  = 15 nm and  = 60 nm for the selective measurement of the fluorophores 
tyrosine and tryptophan, respectively. 
To evaluate the stoichiometry and the binding constant, the double logarithm Stern-Volmer equation 
(DLSV) was considered in first instance (Eq. 1) [4].  
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   (1) 
where F0 and F are the fluorescence intensity in the absence and the presence of a quencher, respectively; 
Kb is the binding constant; nH is the Hill coefficient; and [Qf] is the free quencher (drug) concentration. 
Usually, the free drug concentration [Qf] is unknown and it is replaced by the total drug concentration [Q] 
(it is assumed that the concentration of the macromolecule is negligible with respect to the drug one) (Eq. 
2). Moreover, this equation only yields the binding stoichiometry in case of “infinite” cooperativity [7]. 





   (2) 
The substitution of [Qf] by [Q] indicates that the DLSV equation should be applied only when the 
solution contains a large excess of drug. On the other hand, it is also assumed that the fluorescence 
intensity of the drug is negligible. Therefore, the applicability of the DLSV equation is restricted to these 
scenarios. In order to overcome both problems we have applied an extended version of the non-linear 
least squares program STAR [8], which can handle the spectroscopic data from multiple-equilibria systems 
containing up to 300 solutions, measured at 300 data points. In this case, an equilibrium system can be 
described by a set of components (as albumin, quencher, hydrogen ion, etc.) which can form different 
species. These species are defined by their stoichiometric coefficients and the corresponding binding 
constants: 
s qsS + qQ  S Q           






 . (3) 
STAR uses a chemical equilibrium model, which consists of the components of the system (e.g., HSA and 
drug), together with the guessed stoichiometry and binding constants of the species formed. Moreover, 
the experimental data for each solution contains the total concentrations of components and the 
measured fluorescence spectrum.   
On the other hand, we can consider that the fluorescence spectrum of a given solution is equal to the 
sum of the fluorescence spectra of all species. If we have a set of n fluorescent species, STAR solves the 
mass balances of the components calculating the concentrations for all species for the given set of binding 







  , (4) 
where Ci  indicates the concentration of the i-species, and i,j the relative fluorescence of the i-species at 
the j-wavelength. The i,j values can be supplied as data input, or calculated by the program.  
The binding constants are refined by the Gauss-Newton iterative algorithm, until a minimum of the sum 










    , (5) 
where ns and nw indicate the number of solutions and wavelengths, respectively; the subindexes exp and 
calc indicate experimental values and calculated by the program. 
The program output includes the standard deviation of the errors between experimental and calculated 
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data, together with the estimated error in the binding constants. 
STAR allows the data treatment of the full fluorescence spectra (as it can handle up to 300 solutions, 
measured up to 300 data points in each spectrum), calculating the binding constants and the unitary 
spectrum of the species formed. In this way, the drawbacks owed to the application of the DLSV equation 
are easily overcome.   
Results and Discussion 
When a successive amount of the studied drugs is added to a fixed concentration of HSA, the albumin 
fluorescence is quenched; this is the case of the HSA fluorescence band at about 285 nm. As an example, 
Figure 1 shows the changes in the synchronous fluorescence spectra (60 nm) for HSA after the addition 
of diflunisal.  
 
Figure 1. Quenching study of diflunisal-HSA at synchronous 60 nm 
The DLSV approach uses the fluorescence intensity value of the fluorophore at a fixed wavelength, 
usually the one that offers the maximum intensity. As the drugs used in the study may be fluorescent in the 
working conditions, an initial study of interferences has been performed in the three modes selected. HSA 
shows maximum fluorescence in the emission mode at 340-350 nm, and in the synchronous modes at 285-
288 nm. At these regions, diflunisal does not interfere with HSA, while warfarin (Figure 2) interferes about 
9 % in the emission mode, over 10% in synchronous  60 nm mode and does not interfere in synchronous 
 15 nm mode. Although in some cases interferences exist, we have selected the wavelength with 
maximum fluorescence intensity for each drug and mode to evaluate the results. We assume that the 
interferences under 10% can be evaluated using the DLSV equation. The working conditions are indicated 
in Table 1. 
First, the fluorescence data have been evaluated with the DLSV equation considering the range of linear 
response (0.4-5 or 0.4-14 M, depending on the drug and the fluorescence mode). The results obtained 
show that diflunisal and warfarin interact with HSA with a log Kb value about 5 (Table 2). For diflunisal, not 
significant differences in the log Kb values have been observed when evaluating the data at the three 
modes of acquisition. In the case of warfarin, the log Kb calculated considering the emission mode (where 
warfarin fluorescence interferes about 9 %) is slightly lower than the one obtained taking into account the 
synchronous =15 nm mode (without interferences).   
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Figure 2. Comparison of fluorescence spectra in the study of warfarin-HSA: (a) emission, (b) synchronous 
15 nm and (c) synchronous 60 nm modes 
Table 1. Optimum wavelengths found for the evaluation of the drug-HSA 
interaction for the three modes of interest.  
 
Warfarin Diflunisal 
Emission, λ𝑒𝑥=285 nm 350 nm 348 nm 
Synchronous ∆λ 15 nm 285 nm 286 nm 
Synchronous ∆λ 60 nm - 288 nm 
 
The binding constants have been also evaluated with the modified STAR program. The results are also 
shown in Table 2. In the case of diflunisal, which does not present interferences at the working conditions, 
the results obtained with this program (restricting the model to a 1:1 binding equilibrium) are similar to the 
ones obtained by DLSV equation and are similar at the three modes evaluated. For warfarin, the results 
calculated with the STAR program agree with those obtained with the DLSV approach when there are not 
interferences (synchronous  15 nm). When interferences exist (emission mode), the STAR program is 
able to deal with them and offers log Kb values similar to those obtained in the absence of interferences.  
Moreover, the use of STAR program has allowed detecting the presence of two interactions between 
HSA and diflunisal when it is assumed the possible presence of more than one kind of interaction (Table 2, 
last row). In fact, literature reports that diflunisal can bind to two different sites with different affinity [9]. 
For this drug, the first log Kb value is slightly higher than the one obtained by DLSV equation, but when the 
equilibrium model in STAR contains only one interaction, the results agree with those obtained by DLSV 
equation. In this case, the calculated value by STAR for log Kb is intermediate between log Kb1 and log Kb2, in 
order to accomplish the mass balances of the components. Therefore, when multiple species are involved 
in the binding process, the DLSV approach allows calculating the predominant event, whereas the STAR 
program allows the study of all species in equilibrium.   
a) b) c) 
Clara Ràfols et al.      ADMET & DMPK 6(1) (2018) 000-000 
        52 
Table 2. Stoichiometry and binding constants obtained using two different approaches for data treatment (DLSV equation and STAR program) at three different fluorescence modes. 
  Emission Synchronous  15 nm Synchronous  60 nm 





   1.05(0.07) 5.0(0.3)
a
   - -   





   1.09(0.02) 5.1(0.1)
a
   1.04(0.02) 5.3(0.1)
a
   
STAR
b
 1 5.18(0.01)   1 4.90(0.02)   1 5.34(0.01)   
STAR 1 5.8(0.2) 2 4.7(0.1) 1 5.44(0.04) 2 4.6(0.1) 1 5.7(0.1) 2 4.5(0.2) 
a
: determination coefficient (R
2
) ~ 0.98; 
b




 n2 log Kb2 pH T ( °C) Buffer (Concentration) Ref. 
Warfarin        
1 6.15 - - 7.3 25 PBS (5 mM) [10] 
0.7 5.93 - - 7.3 25 PBS (5 mM, I=50 mM) [10] 
0.5 5.65 - - 7.3 25 PBS (5 mM, I=200 mM) [10] 
0.88 5.56 - - - 27 PBS (10 mM) + NaCl (0.9%) [11] 
- 5.38 - - 7.4 25 PBS (9.5 mM, I=150 mM) [12] 
- 5.36 - - - 25 PBS (50 mM, I=100 mM) [13] 
- 5.45 - 4.15 7.4 25 PBS (67 mM) [14] 
1.38 5.52 - - 7.4 25 PBS (67 mM) [15] 
Diflunisal 
0.53 5.09 - - 7 25 15 mM trisodium citrate (I=150 mM) [16] 
Table 3. Stoichiometry and binding constants reported in the literature for warfarin or diflunisal interactions with HSA. 
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Compared to the results reported by other authors (Table 3) using fluorescence and different 
experimental conditions, the stoichiometry agrees with the reported data (n in the range 0.5-1.38 M). 
The log Kb values obtained in the present work are slightly lower than those obtained by other authors. 
Note that higher ionic strength implies lower log Kb values and therefore the experimental conditions used 
can be meaningful. In the case of diflunisal, the results reported by Davilas et al. [17] agree with the ones 
obtained in the present work when a unique species is considered. Another work on diflunisal interaction 
with HSA [17], using the internal standard electrode method, reports two interactions (log Kb1=5.7, 
log Kb2=3.8) and agrees with the results obtained with the STAR program considering the presence of 
several species. 
Conclusions 
HSA interaction with warfarin and diflunisal has been evaluated using fluorescence measurements. 
First, an interference study has been carried out showing that warfarin interferes under the working 
conditions, while diflunisal does not. Next, the drug-albumin interaction has been studied using two 
different approaches. These drugs bind to the albumin with a Kb in the order of 10
5
. In the absence of 
interferences or when a unique species is considered (stoichiometry 1:1), both approaches yield similar 
values. The modified STAR program is also able to deal with the interferences of fluorescent drugs and can 
consider multiple species. In the case of warfarin, the log Kb values calculated agree in the absence and 
presence of interferences, and in the case of diflunisal it shows that there are two different processes 
involved, with stoichiometry 1:1 and 1:2. 
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